Rep. Pallone's Push For Cosmetics Reform Falls Flat During OTC Monograph Bill Markup
This article was originally published in The Rose Sheet
Executive Summary
The New Jersey Democrat introduced multiple cosmetics-related amendments during the House Health Subcommittee's markup of draft OTC monograph reform legislation. While ultimately nothing came of the proposed measures, it's clear that Pallone remains intent on updating cosmetics regulations to require facility registration, adverse event reporting and good manufacturing practices, among other aims.
You may also be interested in...
Elections Reshape Congress But Not Supplement Industry Regulatory Outlook
Democrats potentially could target tightening regulatory oversight of some industries after regaining a majority in House, but Trump administration's high priority on reducing regulatory burdens bodes well that legislation to expand FDA's current authorities over the US supplement sector will not emerge before Congress' next session opens in 2021. NJ Democrat Frank Pallone could be member of Congress most commonly mentioned and lobbied by supplement industry during next session as Energy and Commerce chairman.
Congressional Races Could Alter Cosmetics Legislative Outlook, Starting With House Energy & Commerce
Recent polling suggests the “blue wave” headed for Congress may not be of the magnitude hyped by some. But if Dems do flip the House as expected, cosmetics reform legislation will go through an Energy & Commerce Committee likely chaired by New Jersey Rep. Frank Pallone, who’s been a highly vocal critic of current cosmetics safety controls.
OTC Monograph Legislation Clears Another Hurdle Despite Exclusivity Concerns
Democrats' opposition to the length of the exclusivity allowed for some new monograph products didn't stop them from voting to send US OTC monograph overhaul legislation on for a vote by the full House. House/Senate differences and some members' questions on whether new exclusivity is needed could make it harder for reforms to pass this year.